Hepatitis Monthly

Published by: Kowsar

Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression

Man Ru Bi 1 , Li Ying Zhu 2 , Bing Zhu Yan 1 , Li Yan Chen 1 , Fu Xiang Wang 2 , Ying Ji Ma 2 , * and Bao Shan Yang 1 , *
Authors Information
1 The Second Clinical Medical College, Harbin Medical University, Harbin, China
2 The Fourth Clinical Medical College, Harbin Medical University, Harbin, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: December 01, 2014, 14 (12); e23552
  • Published Online: December 15, 2014
  • Article Type: Research Article
  • Received: September 12, 2014
  • Revised: November 20, 2014
  • Accepted: November 29, 2014
  • DOI: 10.5812/hepatmon.23552

To Cite: Bi M R, Zhu L Y, Yan B Z, Chen L Y, Wang F X, et al. Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression, Hepat Mon. 2014 ; 14(12):e23552. doi: 10.5812/hepatmon.23552.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7): 2557-76[DOI][PubMed]
  • 2. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10(11): 1111-8[DOI][PubMed]
  • 3. Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep. 2010; 12(3): 186-92[DOI][PubMed]
  • 4. Robbins & Cotran Pathologic Basis of Disease . : 914–17
  • 5. Yan YP, Su HX, Ji ZH, Shao ZJ, Pu ZS. Epidemiology of Hepatitis B Virus Infection in China: Current Status and Challenges. J Clin Trans Hepatol. 2014; 2(1): 15-21[DOI]
  • 6. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology. 2002; 181-182: 43-7[PubMed]
  • 7. Cha C, Dematteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol. 2005; 19(1): 25-37[DOI][PubMed]
  • 8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362(9399): 1907-17[DOI][PubMed]
  • 9. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med. 2008; 14(7-8): 476-84[DOI][PubMed]
  • 10. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006; 17(3): 189-201[DOI][PubMed]
  • 11. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5(4): 331-42[DOI][PubMed]
  • 12. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol. 2008; 20(5): 518-23[DOI][PubMed]
  • 13. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010; 190(5): 881-92[DOI][PubMed]
  • 14. Gong H, Zuliani P, Komuravelli A, Faeder JR, Clarke EM. Analysis and verification of the HMGB1 signaling pathway. BMC Bioinformatics. 2010; 11 Suppl 7[DOI][PubMed]
  • 15. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 2010; 337(1-2): 251-8[DOI][PubMed]
  • 16. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010; 28: 367-88[DOI][PubMed]
  • 17. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res. 2001; 21(6A): 3881-5[PubMed]
  • 18. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003; 17(10): 1295-7[DOI][PubMed]
  • 19. Poser I, Bosserhoff AK. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol. 2004; 19(1): 173-88[PubMed]
  • 20. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol. 2003; 23(8): 2991-8[PubMed]
  • 21. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res. 2003; 63(9): 2188-93[PubMed]
  • 22. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C, et al. Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma. 2008; 49(6): 1184-9[DOI][PubMed]
  • 23. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006; 55(2): 234-42[DOI][PubMed]
  • 24. Ohmori H, Luo Y, Kuniyasu H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets. 2011; 15(2): 183-93[DOI][PubMed]
  • 25. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, et al. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 2012; 55(6): 1863-75[DOI][PubMed]
  • 26. Jiang W, Wang Z, Li X, Li J, Huang Y, Fan X, et al. Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3. Dig Dis Sci. 2012; 57(1): 92-8[DOI][PubMed]
  • 27. Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med. 2012; 10: 135[DOI][PubMed]
  • 28. Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res. 2013; 3(1): 1-20[PubMed]
  • 29. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr.. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998; 281(5383): 1680-3[PubMed]
  • 30. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008; 283(36): 24295-9[DOI][PubMed]
  • 31. de Graaf AO, van Krieken JH, Tonnissen E, Wissink W, van de Locht L, Overes I, et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol. 2005; 130(6): 852-9[DOI][PubMed]
  • 32. Xia L, Xue XZ. Immunohistochemical study of NF-kappaB p65, c-IAP2 and caspase-3 expression in cervical cancer. Oncol Lett. 2012; 3(4): 839-44[DOI][PubMed]
  • 33. Tang D, Lotze MT, Kang R, Zeh HJ. Apoptosis promotes early tumorigenesis. Oncogene. 2011; 30(16): 1851-4[DOI][PubMed]
  • 34. Jiang W, Wang Z, Li X, Fan X, Duan Y. High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res. 2012; 18(2): 293-8[DOI][PubMed]
  • 35. Kohles N, Nagel D, Jungst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol. 2012; 33(6): 2401-9[DOI][PubMed]
  • 36. Dong YD, Cui L, Peng CH, Cheng DF, Han BS, Huang F. Expression and clinical significance of HMGB1 in human liver cancer: Knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol Rep. 2013; 29(1): 87-94[DOI][PubMed]
  • 37. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008; 40(6): 446-52[DOI][PubMed]
  • 38. Tang D, Kang R, Zeh HJ, 3rd., Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010; 1799(1-2): 131-40[DOI][PubMed]
  • 39. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21(2): 139-46[DOI][PubMed]
  • 40. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010; 29(38): 5299-310[DOI][PubMed]
  • 41. Song Q, Wang G, Chu Y, Zhou L, Jiang M, He Q, et al. TNF-alpha up-regulates cellular inhibitor of apoptosis protein 2 (c-IAP2) via c-Jun N-terminal kinase (JNK) pathway in nasopharyngeal carcinoma. Int Immunopharmacol. 2013; 16(2): 148-53[DOI][PubMed]
  • 42. Al Hamoudi W, Khalaf H, Allam N, Al Sebayel M. Coincidental occurrence of hepatocellular carcinoma and cholangiocarcinoma (collision tumors) after liver transplantation: a case report. Hepat Mon. 2012; 12(10 HCC)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments